Buelach, Switzerland, 2 July 2010 - BIOTRONIK AG, a leading manufacturer of Vascular Interventional devices, announced the introduction of the first in the world 200 mm, 4F compatible, self-expanding stent dedicated for the treatment of long disease segments in Superficial Femoral Artery (SFA) and Infrapopliteal arteries.
BIOTRONIK has now leapt ahead of competitors and positioned its peripheral intervention products for lower limb disease to stand out as the only company globally that can offer a complete “4F Solutions” package.
The new Pulsar-18 device is available in diameters 4-7 mm suitable for treatment of both SFA and below knee disease with lengths up to 200 mm. The stent has an improved radial force, flexibility and fracture resistance compared to competitor devices. This is especially important in SFA where data with stiffer, previous generation, stents have only provided moderate results. A new study, 4-EVER, will be looking at providing clinical data supporting the improved efficacy of this 5th generation stent design.
Available on 0.018”/4F platform, it completes the 4F Solutions portfolio that the company has been working on. When used together with the 0.018” Cruiser-18 wire, 4F Fortress sheath and 0.018”/4F Passeo-18, minimally invasive intervention of the lower limb is now truly possible.
Alain Aimonetti, Vice President Sales and Marketing commented, “Pulsar-18 is the single most important addition to our already developed portfolio for lower limb intervention. We believe, together with physicians, that the ability to treat patients with 4F low profile devices will change the future of peripheral intervention. The aim is that patients will be able to have treatment on a day-case basis and suffer less puncture site complications. Physicians will appreciate a higher technical success and lower re-intervention rate due to the improved long-term outcomes with this dedicated stent design”.
The company is now able to offer guide wires, angioplasty balloons, 4F introducer sheaths and both balloons and self-expandable stents, all on 4F. The soon to be released drug-eluting balloon will further enhance treatment options available for physicians. BIOTRONIK steps up to take and hold the primary position as a partner for physicians treating lower limb disease”.
European launch in July 2010 will be immediately followed by worldwide introduction.
About BIOTRONIK SE & Co. KG
As one of the world’s leading cardiovascular medical device companies, with several million implanted devices, BIOTRONIK is represented in over 100 countries with its global workforce of more than 5100 employees. Known for having its fingers on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.
For more information about Pulsar-18, please click here